Bristol-Myers Squibb enters a multi-year strategic agreement with Concerto HealthAI to use machine learning to aid in protocol design for precision treatment and improved patient outcomes. (outsourcing-pharma.com)
How is artificial intelligence (AI) impacting clinical trials?
There is much talk about clinical trial recruitment and using AI to mine electronic medical records (EHRs). Other applications include protocol design and optimization, and risk-based monitoring; site selection is primed for disruption with machine learning and AI. (Clinical Leader)
Current Feature
Guest interview. Leveraging artificial intelligence to manage clinical trials
Leveraging artificial intelligence to manage clinical trials An interview with Kim Walpole, Co-Founder and CEO of Trials.ai. Conducted by Tatsiana Vertak Tatsiana: What does Trials.ai do? Kim: At Trials.ai we are on a mission to get treatments to patients faster by optimizing clinical trial protocols for speed and success. We Read more
Solving pharma’s ‘big text’ problem with NLP
There are about 27m articles in PubMed and 280,000 studies on ClinicalTrials.gov – so how does the industry begin to make sense of all this data? (outsourcing-pharma.com)
How in silico trials are making personalized medicine a reality
The biopharma industry is on the precipice of making personalized medicine a reality with access to massive amounts of data, computing power, and artificial intelligence to run in silico clinical trials, says GNS Healthcare CEO. (outsourcing-pharma.com)
Conservatism of pharmaceutical industry a barrier to AI and machine learning
www.clinicalinformaticsnews.com
Senior Director at Cytel believes that artificial intelligence and machine learning are going to change the clinical development paradigm, but there are challenges to overcome before AI and machine learning will be useful in clinical trials. Challenges include availability of data and the opinions of pharmaceutical companies and regulators. (Clinical Informatics News)
AI companies may be the “Deux ex Machina” of pharmaceutical R&D
“Although pharmaceutical companies spend over $172 billion on research and development annually, over 90% of molecules discovered using traditional techniques fail in human clinical trials.” AI may be the “Deux ex Machina” in the field of pharmaceutical R&D. Deep Knowledge Analytics publishes their list of AI companies that are solely dedicated to scientific R&D. (Forbes)
Blockchain a potential “disruptive innovation” in clinical research
www.appliedclinicaltrialsonline.com
Blockchain technology- a decentralized and encrypted way of distributing, sharing, and storing information – has the capability to transform the clinical research industry by providing a safe way to collect, store, and make accessible patient data. It could help to streamline communication between doctors and patients during a trial, increase patient engagement, and improve patient recruitment and retention. (Applied Clinical Trials)
AI and big data might solve clinical trial challenges
Artificial intelligence (AI) technology, combined with big data, has the potential to solve clinical trial challenges, including increasing trial efficiency, reducing trial costs, informing clinical trial development, and keeping patients engaged. One-third of survey respondents said technologies that leverage big data and AI would have the most impact improving clinical trial efficiency. (Clinical Leader)
More data will be generated in 2019 than in the last 5,000 years
The new year will bring more data than the last 500 decades, information that will be used to improve clinical trial design and shorten drug development timelines, say industry experts. (outsourcing-pharma.com)